Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) is increasingly used in clinical microbiological laboratories to identify bacteria and fungi at a species level and to subtype them. The cfiA gene encoding the unique carbapenemases found in Bacteroides is restricted to division II Bacteroides fragilis strains. The aim of this study was to evaluate whether MALDI-TOF MS is suitable for differentiating B. fragilis strains which harbour the cfiA gene from those that do not. A well-defined collection of 40 B. fragilis isolates with known imipenem MICs (0.062-.32 mg l "1 ) were selected for this study. Twelve B. fragilis strains with known cfiA status, including NCTC 9343 (division I) and TAL3636 (division II), were measured by means of microflex LT MALDI-TOF MS and well-defined differences in mass spectra between the cfiA-positive and cfiA-negative strains were found in the interval 4000-5500 Da. A further 28 strains were selected for the blind measurements: 9 cfiA-positive clinical isolates with different imipenem MICs ranging between 0.06 and .32 mg l "1 (different expressions of the metallo-b-lactamase gene) were clearly separated from the 19 cfiA-negative isolates. The presence or absence of the selected peaks in all tested strains clearly differentiated the strains belonging to B. fragilis division I (cfiA-negative) or division II (cfiA-positive). These results suggest a realistic method for differentiating division II B. fragilis strains (harbouring the cfiA gene) and to determine them at a species level at the same time. Although not all cfiA-positive B. fragilis strains are resistant to carbapenems, they all have the possibility of becoming resistant to this group of antibiotics by acquisition of an appropriate IS element for full expression of the cfiA gene, leading to possible treatment failure.
INTRODUCTION
Bacteroides fragilis, one of the most important species in the Bacteroides genus, is the leading anaerobic pathogen in human monobacterial or polymicrobial infections (Aldridge et al., 2003) . It is part of the Cytophaga-Flavobacterium-Bacteroides group (Gherna & Woese, 1992) , which is distant in evolutionary terms from most other bacteria of medical interest. The genus Bacteroides appears to be one that evolves rather rapidly (Shah, 1990) and molecular genetic methods have led to novel, highly related species being included in the genus recently; however, some other species have been removed (Song et al., 2004 (Song et al., , 2005 Sakamoto & Benno, 2006) . Members of the Bacteroides genus, including B. fragilis, often exhibit resistance to different drugs, such as b-lactam and b-lactamase inhibitor combinations, clindamycin, fourthgeneration fluoroquinolones, metronidazole or carbapenems, used for treatment of infections involving anaerobes. Their correct species identification may be necessary because the resistance to different anti-anaerobic drugs may differ according to the species (Snydman et al., 2007) . Matrixassisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) has been shown to constitute a useful and simple method for the rapid identification of different human pathogenic bacteria, including Bacteroides strains, based on the spectrum of constantly expressed high-abundance proteins such as ribosomal proteins or to a less extent the highly prevalent housekeeping proteins (Bizzini & Greub, 2010; Nagy et al., 2009) . Only a few studies have as yet been performed with this method to prove the presence of resistance mechanisms. Cell wall and proteome-related structural alterations reflected in the mass spectra of meticillin-resistant Staphylococcus aureus as compared with meticillin-sensitive strains were described some years ago (Edwards-Jones et al., 2000) , and a 'proteome shift' in Candida albicans that corresponds to its fluconazole MIC measured by conventional methods was reported recently (Marinach et al., 2009) .
Despite the fact that B. fragilis isolates appear phenotypically homogeneous, DNA-DNA hybridization experiments have proven that they may be divided into two DNA homology groups, I and II, which display 65-70 % intergroup and 80-90 % intragroup similarity (Johnson, 1978; Johnson & Ault, 1978; Gutacker et al., 2000) . The two divisions of B. fragilis can be distinguished by ribotyping and analysis of the fragment patterns generated by arbitrarily primed PCR or multilocus enzyme electrophoresis (Gutacker at al., 2000 (Gutacker at al., , 2002 Podglajen et al., 1995; Ruimy et al., 1996) . Two chromosomal cephalosporinase genes have been described in B. fragilis. The cepA gene encodes a class 2e cephalosporinase (Parker & Smith, 1993) . The production of CepA leads to resistance to most b-lactam antibiotics, with the exception of the cephamycins, the carbapenems and the b-lactamase inhibitor combinations. The other chromosomal b-lactamase gene is cfiA (also known as ccrA), which expresses a class B metallo-b-lactamase that confers resistance in B. fragilis to all b-lactam antibiotics, including carbapenems (Rasmussen et al., 1990) . For the expression of this gene, special insertion sequence (IS) elements are needed immediately upstream of the cfiA gene to act as a promoter (Podglajen et al., 1994) . The presence of the cfiA gene on the chromosome of randomly selected B. fragilis clinical isolates is much more frequent (2.4-6.9 %) than carbapenem resistance (~1 %) detected during resistance surveillances (Nagy, 2010) . A silent cfiA gene has been shown to be expressed, leading to carbapenem resistance, if the necessary IS element, present in any other part of the chromosome, is inserted in the appropriate upstream region of the gene (Podglajen et al., 1994) . The cfiA gene can be detected only on the chromosome of B. fragilis strains belonging to division II (Gutacker et al., 2000; Podglajen et al., 1995) .
The aim of the present study was to use MALDI-TOF MS to distinguish B. fragilis strains which harbour the cfiA gene from those which do not, thereby providing a possibility for differentiating B. fragilis strains belonging to divisions I and II by this method.
METHODS
Isolates. Thirty-eight B. fragilis strains were selected from our strain collection for this study; they had known imipenem MICs, and had previously been characterized by PCR and sequencing for the presence of the cfiA gene and IS elements in the chromosome (Table 1 ). All these strains were clinical isolates originating from different resistance surveillance studies carried out locally or on a European level; some of them originated from the USA. B. fragilis NCTC 9343 and TAL3636 were used as control strains belonging to division I and II, respectively. In the second part of the study, the spectra of 145 B. fragilis strains previously identified by MALDI-TOF MS (Nagy et al., 2009 ) were reevaluated in a search for specific peaks found characteristic of division I or II of B. fragilis in the first part of the study. All strains were stored in cryobank vials (Mast Diagnostics) and cultured on Columbia agar base (Oxoid) supplemented with 5 % (v/v) cattle blood, haemin (1 mg l 21 ) and vitamin K 1 (5 mg l 21 ) for 24-48 h at 37 uC in an anaerobic chamber (Concept 400; Ruskinn Technology). Imipenem MIC measurements were carried out using Etest (AB Biodisk).
Detection of the cfiA gene and IS elements. PCR detection of the cfiA gene and the IS elements upstream of the resistance gene (PCR mapping) or in other parts of the chromosome was carried out as previously described (Só ki et al., 2004 (Só ki et al., , 2006 .
Sample preparation for MALDI-TOF MS measurement. One colony of each bacterial strain, which had been subcultured for 24 h in an anaerobic environment, was transferred into an Eppendorf vial and carefully suspended in 300 ml bidistilled water. Ethanol (900 ml) was added to the suspension, and mixed well. For MALDI-TOF MS analyses the stabilized samples were sent from the Anaerobe Reference Laboratory in Hungary to the Bruker laboratory in Bremen (Germany). Further sample preparation was carried out as described previously (Nagy et al., 2009) . In brief, the samples were centrifuged (13 000 g for 2 min), the supernatants were removed and the pellets were dried at room temperature and resuspended in 50 ml 70 % aqueous formic acid and 50 ml acetonitrile. After centrifugation (13 000 g for 2 min), 1 ml of the supernatant was placed onto the MALDI target plate and dried at room temperature, followed by adding 2 ml MALDI matrix (saturated solution of a-cyano-4hydroxycinnamic acid in 50 % acetonitrile/2.5 % trifluoroacetic acid).
MALDI-TOF MS measurement. All measurements were performed on a microflex LT MALDI-TOF mass spectrometer in the linear positive ion mode, with a laser frequency of 60 Hz. The mass range was 2000-20 000 Da. For each sample, the sum spectra of 240 single spectra were acquired, in portions of 40 single spectra from 6 different positions on a spot. For each sample, at least 20 separate sum spectra were collected.
Data processing. The mass spectra generated for the analysed bacteria were identified as derived from B. fragilis strains by using the MALDI Biotyper 2.0 software and database (version 3.1.1.0., 3740 entries; Bruker Daltonik). Identification was performed with the standard pattern matching approach as recommended by the manufacturer, applying log(score) ¢2.0 for species identification.
For the detection of cfiA-positive and cfiA-negative specific peaks, respectively, mass spectrum sets of well-defined cfiA-positive and cfiA-negative B. fragilis strains were imported in the ClinProTools 2.2 software (Bruker Daltonik). Spectra were normalized and recalibrated using the respective functionalities of the software. Subsequently, group-characteristic peaks and peak shifts were searched for by careful visual investigation of the spectrum sets. In addition, peak variations between the two groups were investigated by using the FlexAnalysis 3.3 software (Bruker Daltonik).
Correlation analysis was performed using the MALDI Biotyper 2.0 software with standard settings (mass range 3000-12 000 Da, resolution 4, eight intervals, autocorrelation off). Twenty different profile spectra were used for each strain in this analysis. Principle component analysis was carried out with the respective ClinProTools 2.2 algorithm for normalized data.
Main spectra (MSP) for the creation of a cfiA-positive/cfiA-negative differentiating library were calculated from six strains each of which had previously been demonstrated to belong to division II or division I. This resulted in a library containing two reference entries: one specific for cfiA-positive and one for cfiA-negative B. fragilis strains. MSP calculations relating to the cfiA-positive/cfiA-negative library and pattern matching against the created library were performed by using MALDI Biotyper 2.0 with standard settings.
RESULTS
Twelve B. fragilis strains (six cfiA-positive and six cfiAnegative) were selected for the first measurement. Besides the two control strains (NCTC 9343, cfiA-negative strain; and TAL3636, cfiA-positive strain), ten clinical isolates were involved. All isolates had previously been identified as B. fragilis and investigated in detail for the presence of the cfiA gene, the IS elements and the level of imipenem resistance. After the routine measurements, microflex LT MALDI-TOF MS differences were looked for. Figs 1 and 2 show characteristic differences in the interval 4000-5500 Da, visualized by the gel/stack view in ClinProTools with Flexanalysis software. A further 28 strains were selected for the blind measurements: 9 further cfiA-positive clinical isolates with different imipenem MICs (different expressions of the metallo-b-lactamase gene) ranging between 0.06 and .32 mg l 21 , and 19 cfiA-negative isolates with imipenem MICs between ,0.125 and 0.5 mg l 21 , previously selected from our culture collection and tested for possible silent carriage of the gene. During the two measurements, the presence or absence of the selected peaks in the MALDI-TOF spectrum between 4600 and 10 600 allowed a 100 % distinction between the strains belonging to B. fragilis division I (cfiA-negative) or division II (cfiA-positive) ( Supplementary Table S1 in JMM Online).
In a previous collaborative study (Nagy et al., 2009) , 277 clinical Bacteroides isolates were identified at a species level by MALDI-TOF MS. From among these, the spectra of 145 B. fragilis isolates with a high log(score) (¢2.5) were reevaluated and the characteristic peaks defined earlier for division II were looked for. Nine isolates (6.2 %) belonged to B. fragilis division II (Table 2) . All nine isolates were cfiApositive, with imipenem MICs varying between ,0.125 and .32 mg l 21 . Even isolates with silent carriage of the cfiA gene were detected by this method. Two of the characteristic peaks (4826 and 9649 Da) were found in all nine strains and a third one (9375 Da) was present in eight of the nine strains.
For further statistical analysis, composite correlation index analysis was performed with profile spectra from the initial six cfiA-positive strains and six cfiA-negative strains. The correlation between the different cfiA-positive strains was found to be 0.84-0.97, while that in the cfiA-negative group was 0.86-0.98. In contrast with these high correlations within the two groups, the correlation indices calculated for strains from different groups (i.e. cfiA-positive vs cfiA-negative) were only 0.45-0.62, confirming the clear spectral difference between strains harbouring or not the cfiA gene. Principle component analysis performed with the initial 12 B. fragilis strains also resulted in a clear separation of two clusters, consisting of cfiA-positive and cfiA-negative strains, respectively.
To investigate the possibility of predicting cfiA-negative and cfiA-positive B. fragilis strains with the MALDI Biotyper pattern matching approach, a small library containing only two reference spectra (MSP), one specific for cfiA-negative and one for cfiA-positive strains, was calculated from the B. fragilis division I and division II strains from the first test set. This library was challenged with spectra of the 9 further cfiA-positive and 19 randomly selected cfiA-negative strains (three spectra per strain). In all cases, the MALDI Biotyper software classified the B. fragilis strains correctly, indicating the suitability of such an approach for the classification of divisions I and II of B. fragilis (data not shown).
DISCUSSION
Since the introduction of MALDI-TOF MS for pure microbiological applications, it has evolved from an experimental tool to a technology with significant benefit for routine as well as for scientific investigations. It is currently applied especially in clinical microbiology for the identification of various bacteria or fungi at a species or subspecies level after a positive culture, as it requires very limited time for sample preparation and measurement (Bizzini & Greub, 2010; Nagy et al., 2009; Murray, 2010) . At present, very little information is available on the use of this technique for the direct identification of pathogens from clinical samples with or without preculturing (Drancourt, 2010) or for determination of the antibiotic resistance of isolated pathogens (Edwards-Jones et al., 2000; Marinach et al., 2009) .
The results of the present study demonstrate the applicability of MALDI-TOF MS for both the subtyping and the detection of the presence of an important resistance mechanism of B. fragilis, a frequently isolated anaerobic pathogen. With the successful differentiation of B. fragilis strains belonging to divisions I and II at the same time as their identification at a species level by MALDI-TOF MS, it is possible to predict the presence of an important resistance phenotype with respect to carbapenems, one of the most important group of antimicrobials used in treating mixed infections. The carbapenem resistance of B. fragilis is due to a speciesspecific metallo-b-lactamase, which is encoded by the cfiA (ccrA) gene of the organism. Almost 100 % of the carbapenem-resistant Bacteroides strains are cfiA-positive B. fragilis isolates. The recognition that B. fragilis can be subgrouped into two divisions dates back to the late 1970s, when Johnson & Ault (1978) demonstrated differences in DNA-DNA homology rates not only between the known Bacteroides species, but also between two groups of strains of B. fragilis subsp. fragilis (now B. fragilis). Cloning and sequencing of the metallo-blactamase gene allowed screening of the B. fragilis population, which demonstrated that there are strains that are not imipenem-resistant despite harbouring the cfiA resistance gene; in the case of strains with high-level resistances to imipenem, an activator IS element is needed to insert upstream of the cfiA gene in normal flora, and clinical or experimental isolates (Podglajen et al., 1994; Só ki et al., 2000 Só ki et al., , 2004 . Further investigations revealed that the cfiA-positive strains belong only to division II, and the cfiA-positive and -negative strains can be differentiated by various molecular typing methods (Gutacker et al., 2000; Podglajen et al., 1995; Terhes et al., 2007) . The finding that the genome and the most important housekeeping genes and rRNA gene sequences differentiate the two divisions reflects the fact that the differences emerged during the early evolution of the species. Through the use of MALDI-TOF MS to identify ribosomal proteins in the present study, the two divisions of B. fragilis can be differentiated in a relatively cheap and up-to-date manner. During the time of publication of our results, Wybo et al. (2011) using MALDI Biotyper showed through preparing a dendrogram or using the composite correlation index the clear separation of cfiA-positive (n541) and cfiA-negative (n5207) B. fragilis strains from their collection.
As concerns the cfiA-positive B. fragilis isolates selected for our study, the expression of their resistance and genetic background had previously been investigated in detail: (i) phenotypically resistant strains (MIC ¢16 mg l 21 ) with IS elements in the upstream region of the cfiA genes; (ii) phenotypically resistant strains (MIC ¢16 mg l 21 ) or with elevated imipenem MICs (1 and 8 mg l 21 ), but without IS elements upstream of the cfiA genes; and (iii) phenotypically fully susceptible strains (MIC ¡0.25 mg l 21 ) without IS elements upstream of the cfiA genes. These three groups of strains could not be distinguished by MALDI-TOF MS, which confirms that more significant genetic changes than merely the movement of IS elements in the genome are responsible for the differences in the MS spectrum. The second group of cfiA-positive isolates mentioned above has not yet been sufficiently well characterized as regards the exact expression mechanisms, but our investigations demonstrated that these strains are heterogeneously resistant to carbapenems and may utilize a weak self-promoter of the cfiA genes (Rasmussen et al., 1990; Podglajen et al., 1994; our unpublished results) .
Recent results have demonstrated that the cfiA genes in some B. fragilis strains belonging to division II are located in a contiguous sequence with other unrelated genes that replace a portion of a chromosomal segment in the sequenced genome of B. fragilis NCTC 9343 belonging to division I (Thompson & Malamy, 1990 ). However, it has been shown that the cfiA genes may be present in multiple copies in the genomes in some strains (Podglajen et al., 1994 ; our unpublished results). Our explanation for these phenomena is that the chromosomal segment carrying the cfiA gene and the accompanying genes forms a genetic element which can be mobile within a strain, but whose transfer between the two divisions is restricted.
Although not all cfiA-positive B. fragilis strains are resistant to carbapenems, they all have the potential to become resistant to this important group of antibiotics by acquisition of an appropriate IS element for full expression of the cfiA gene. Confirmation by MALDI-TOF MS of the separation of the B. fragilis genomic divisions at the same time as the species determination could be useful in clinical microbiology laboratories for the detection of resistance to this important antibiotic in B. fragilis.
